KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 13 years of Amortization of Deferred Charges data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 17.56% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $6.9 million, up 3.26%, while the annual FY2025 figure was $6.9 million, 3.26% up from the prior year.
  • Amortization of Deferred Charges reached $2.0 million in Q4 2025 per IONS's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q4 2025 and bottomed at $860000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $1.5 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Amortization of Deferred Charges: soared 61.79% in 2021, then decreased 3.3% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $1.4 million in 2021, then decreased by 2.48% to $1.3 million in 2022, then grew by 24.36% to $1.7 million in 2023, then rose by 0.6% to $1.7 million in 2024, then rose by 17.56% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $2.0 million in Q4 2025, $1.7 million in Q3 2025, and $1.6 million in Q2 2025.